GPP
CLYM

Great Point Partners’s Climb Bio CLYM Stock Holding History

Great Point Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.14M Buy
1,334,130
+354,596
+36% +$2.05M 2.1% 18
2025
Q4 		$3.92M Buy
+979,534
New +$2.35M 1.27% 25
2024
Q4 		– Sell
-248,168
Closed -$1.26M – 34
2024
Q3 		$1.26M Buy
+248,168
New +$1.76M 0.37% 30

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Great Point Partners's CLYM Position: Q1 2026 in Review

Great Point Partners increased its Climb Bio (CLYM) stake by 36% in Q1 2026, buying an estimated $2.05M and bringing the position to 1,334,130 shares worth $9.14M. The position accounts for 2.1% of the portfolio, ranked #18.

Great Point Partners first reported a position in CLYM in Q3 2024 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Great Point Partners held 1,334,130 shares of Climb Bio worth $9.14M as of Q1 2026.
  • Great Point Partners bought 354,596 Climb Bio shares in Q1 2026, an estimated $2.05M.
  • Climb Bio made up 2.1% of Great Point Partners's portfolio in Q1 2026, its #18 holding.
  • Great Point Partners first reported a position in Climb Bio in Q3 2024 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.